Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

the control group at 51% (p(less than or =)0.05). There was no statistically significant difference between PolyHeme and control patients for the other efficacy endpoints. -0-



                               TABLE 2

                           DAY 1 MORTALITY



                                        PolyHeme        Control

                                       (deaths/N)  %   (deaths/N)  %

 ------------------------------------- ---------- ---- ---------- ----

 MITT                                   34/350    9.7   27/364    7.4

 ------------------------------------- ---------- ---- ---------- ----

 AT                                     33/349    9.5   28/365    7.7

 ------------------------------------- ---------- ---- ---------- ----

 PP                                     20/279    7.2   21/307    6.8

 ------------------------------------- ---------- ---- ---------- ----

Safety Analysis

The primary safety endpoints in the study were Day 1 mortality, Day 30 mortality, and durable serious adverse events (SAEs). Durable serious adverse events were prospectively defined as SAEs which resulted in a "permanently disabling" outcome. There were two durable SAEs in each group. There was no statistically significant difference between the PolyHeme and control groups for any of these endpoints.

Additional Safety Data

All adverse events (AEs), serious adverse events (SAEs), cardiac SAEs, and myocardial infarction (MI) were also analyzed. The overall incidence of AEs in the PolyHeme group of 93% (324 patients) was higher than that in the control group of 88% (322 patients), (p(less than or =)0.05). The most common AEs in both groups were: anemia, fever, and electrolyte imbalances. The overall incidence of SAEs in the study was 40% (141 patients) in the PolyHeme group and 35% (126 patients) in the control group (pgreater than or 0.05). The most common SAEs in both groups were: shock, pneumonia, and respiratory failure.


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:8/27/2015)... PLYMOUTH MEETING, Pa. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... is decommissioning the Da Vinci S™ surgical robot, hospitals ... robot replacement plans. They also need to see where ... right procedures on the right patients? Have they adopted ... their robotic surgery program in the future? ...
(Date:8/27/2015)... , Aug. 27, 2015   NineSigma the ... drive over $450M in estimated overall revenue growth and anticipates ... Ohio Third Frontier Open Innovation Incentive (OII). ... awarded NineSigma a grant of over $2 million to accelerate ... companies between $10 Million and $1 Billion in revenues. To ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, ... courtroom.  Attorneys representing two southern Nevada ... including death, after using the diabetes drug Actos. ... company knew, that their drug Actos caused an increased risk ... order to hold Takeda responsible it is appropriate to seek ...
Breaking Medicine Technology:ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 32 Billion Dollar Verdict Sought In Actos Trial 2
... The World Health Organization (WHO) has granted prequalification to ... immunization of infants and children from 6 weeks through ... otitis media caused by the 13 pneumococcal serotypes (1, ... 19A, 19F and 23F) contained in the vaccine. WHO ...
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS ; ... financial results for the fiscal 2010 fourth quarter and year ... August 30, 2010. Management has scheduled a ... 30, 2010 (Tuesday, August 31 at 6.30 a.m. AEST) ...
Cached Medicine Technology:World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 2World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 3World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 4World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 5World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 6World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 7Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010 2
(Date:8/27/2015)... ... 2015 , ... In an article published July 30th by the ... New Orleans, highlighting a security firm that is tasked with providing supplemental protection. Called ... who worked with the city to provide private security when it is needed in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), part ... medical centers in the United States to receive international recognition for an advanced, ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated ...
(Date:8/27/2015)... Michigan (PRWEB) , ... August 27, 2015 , ... On ... returned for the second year as sponsor of the “Music With A Mission” benefit ... raise money for music education programs in the underfunded school districts of Mendon and ...
(Date:8/27/2015)... ... 27, 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to ... honoring eight heroes who have made significant contributions in the field of rare blood ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is ... October 27-29, 2015 in San Jose, CA. The first event dedicated to ... the void that exists where battery development and energy storage innovation are concerned. ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
... 1960s, surgeons experimented by transplanting chimpanzee organs into humans in ... a baboon heart and survived 20 days. Since then, doctors// ... organs, tissues and cells to treat various diseases, all with ... surrounding cross-species transplant -- also known as xenotransplantation. ...
... common treatment option for HIV patients is associated with ... a new study. However, researchers say the benefit of ... for most patients. ,Combination antiretroviral therapy substantially ... AIDS. Before this therapy was available, the annual mortality ...
... for centuries, doctors say. But only recently has it been ... migraines or neck- and head-squeezing tension headaches //that are present ... think it sounds like just another excuse to skip school. ... freshman from St. Cloud, Minnesota, know how serious the condition ...
... is a common health problem worldwide. Both osteoarthritis and ... There is no cure for arthritis and no effective ... study could help lead doctors towards a drug to ... molecular pathway and an enzyme that play a pivotal ...
... caused a recent outbreak of Hepatitis A in Pennsylvania ... ,Bill Zavertnik, Chi-Chi's chief operating officer, said in ... were not the source of the outbreak, that there ... outbreak and that it was an isolated incident. , ...
... new study shows a new drug alternative to warfarin in ... The research shows the drug ximelagatran appears to be as ... for people at high risk of stroke because of its ... include an increased risk of bleeding and a possible interaction ...
Cached Medicine News:Health News:Animals can give us a second chance at life 2Health News:HIV Treatment Said to Increase Heart Attack Risk 2Health News:Finding relief from Excruciating Headaches a challenge 2Health News:Finding relief from Excruciating Headaches a challenge 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: